ZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, PR China.
Eur J Med Chem. 2019 Oct 15;180:72-85. doi: 10.1016/j.ejmech.2019.07.017. Epub 2019 Jul 7.
A series of pyrazole-thiophene derivatives exhibiting good Akt inhibitory activities were obtained on the basis of conformational restriction strategy, leading to the discovery of compound 1d and 1o which showed excellent in vitro antitumor effect against a variety of hematologic cancer cells and their potential of inducing apoptosis, blocking the cell cycles at S phase and significantly inhibiting the phosphorylation of downstream biomarkers of Akt kinase of cancer cells. Amongst, compound 1o also exhibited good PK profiles and inhibited about 40% tumor growth in MM1S xenograft model. Compound 1o might be a potential candidate for further development.
基于构象限制策略,我们获得了一系列表现出良好 Akt 抑制活性的吡唑并噻吩衍生物,发现了化合物 1d 和 1o,它们对多种血液系统癌细胞具有优异的体外抗肿瘤作用,并具有诱导细胞凋亡、将细胞周期阻滞在 S 期和显著抑制 Akt 激酶下游生物标志物磷酸化的潜力。其中,化合物 1o 还表现出良好的 PK 特征,在 MM1S 异种移植模型中抑制约 40%的肿瘤生长。化合物 1o 可能是进一步开发的潜在候选药物。